RO 415253

Drug Profile

RO 415253

Alternative Names: RO 41-5253

Latest Information Update: 29 Aug 2002

Price : $50

At a glance

  • Originator Roche
  • Class Retinoids
  • Mechanism of Action Apoptosis stimulants; Retinoic acid receptor alpha antagonists; Retinoic acid receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Breast cancer

Most Recent Events

  • 17 May 1999 A preclinical study has been added to the pharmacodynamics section
  • 05 Mar 1999 New profile
  • 05 Mar 1999 Preclinical development for Breast cancer in European Union (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top